vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $34.1M, roughly 1.0× ZEVRA THERAPEUTICS, INC.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs -3.2%). ZEVRA THERAPEUTICS, INC. produced more free cash flow last quarter ($5.5M vs $-2.4M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs -3.5%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
CLFD vs ZVRA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $34.1M |
| Net Profit | $-614.0K | — |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | 27.3% |
| Net Margin | -1.8% | — |
| Revenue YoY | -3.2% | 183.4% |
| Net Profit YoY | 67.8% | — |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $34.1M | ||
| Q3 25 | $23.4M | $26.1M | ||
| Q2 25 | $49.9M | $25.9M | ||
| Q1 25 | $47.2M | $20.4M | ||
| Q4 24 | $29.7M | $12.0M | ||
| Q3 24 | $5.6M | $3.7M | ||
| Q2 24 | $48.8M | $4.4M | ||
| Q1 24 | $36.9M | $3.4M |
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | $-544.0K | ||
| Q2 25 | $1.6M | $74.7M | ||
| Q1 25 | $1.3M | $-3.1M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-33.2M | ||
| Q2 24 | $-447.0K | $-19.9M | ||
| Q1 24 | $-5.9M | $-16.6M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | 27.3% | ||
| Q3 25 | 10.3% | 15.9% | ||
| Q2 25 | 3.0% | -274.5% | ||
| Q1 25 | 0.6% | -26.3% | ||
| Q4 24 | -6.9% | -128.0% | ||
| Q3 24 | — | -739.0% | ||
| Q2 24 | -4.7% | -534.8% | ||
| Q1 24 | -26.4% | -598.1% |
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | -2.1% | ||
| Q2 25 | 3.2% | 288.7% | ||
| Q1 25 | 2.8% | -15.2% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -899.2% | ||
| Q2 24 | -0.9% | -447.9% | ||
| Q1 24 | -16.0% | -485.3% |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | $-0.01 | ||
| Q2 25 | $0.11 | $1.21 | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $-0.69 | ||
| Q2 24 | $-0.04 | $-0.48 | ||
| Q1 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $249.7M | $154.7M |
| Total Assets | $268.1M | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $62.4M | ||
| Q3 25 | $106.0M | $54.4M | ||
| Q2 25 | $117.2M | $47.7M | ||
| Q1 25 | $112.0M | $37.3M | ||
| Q4 24 | $113.0M | $33.8M | ||
| Q3 24 | $129.0M | $54.0M | ||
| Q2 24 | $123.8M | $39.3M | ||
| Q1 24 | $142.9M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | $154.7M | ||
| Q3 25 | $256.2M | $133.2M | ||
| Q2 25 | $264.5M | $117.2M | ||
| Q1 25 | $265.9M | $41.0M | ||
| Q4 24 | $267.4M | $39.7M | ||
| Q3 24 | $275.8M | $69.8M | ||
| Q2 24 | $274.6M | $32.5M | ||
| Q1 24 | $279.2M | $48.8M |
| Q4 25 | $268.1M | $284.7M | ||
| Q3 25 | $306.2M | $270.1M | ||
| Q2 25 | $314.7M | $256.3M | ||
| Q1 25 | $310.9M | $172.7M | ||
| Q4 24 | $303.2M | $178.1M | ||
| Q3 24 | $315.3M | $191.6M | ||
| Q2 24 | $318.1M | $144.4M | ||
| Q1 24 | $315.4M | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $5.5M |
| Free Cash FlowOCF − Capex | $-2.4M | $5.5M |
| FCF MarginFCF / Revenue | -7.1% | 16.1% |
| Capex IntensityCapex / Revenue | 2.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $5.5M | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | $7.9M | $-3.6M | ||
| Q1 25 | $3.0M | $-8.2M | ||
| Q4 24 | $7.2M | $-16.3M | ||
| Q3 24 | $22.2M | $-18.1M | ||
| Q2 24 | $4.0M | $-19.1M | ||
| Q1 24 | $-5.7M | $-16.2M |
| Q4 25 | $-2.4M | $5.5M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | $7.5M | $-3.8M | ||
| Q1 25 | $654.0K | $-8.3M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $18.2M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-7.7M | — |
| Q4 25 | -7.1% | 16.1% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | 15.1% | -14.7% | ||
| Q1 25 | 1.4% | -40.8% | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 323.0% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -20.8% | — |
| Q4 25 | 2.9% | 0.1% | ||
| Q3 25 | 2.0% | 2.1% | ||
| Q2 25 | 0.8% | 0.8% | ||
| Q1 25 | 5.1% | 0.5% | ||
| Q4 24 | 7.0% | 0.0% | ||
| Q3 24 | 71.4% | 0.0% | ||
| Q2 24 | 2.5% | 0.0% | ||
| Q1 24 | 5.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | -0.05× | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
